Archive
1319 articles, sorted by publication time.
A receptor structure embedded in the cell membrane may offer a new approach to reducing inflammation. Researchers used computational design to create synthetic proteins that reduced signaling downstream of TLR4 in human cells. But delivering them to their target and determining whether they can improve disease remain key challenges before the approach can become a treatment.
Two UK hospitals incorporated autonomous AI into their suspected skin cancer referral pathways, estimating savings of 2,851 hours of physician time over 16 months. The prospect of increased capacity is promising, but six missed cases are a reminder that safety monitoring must continue throughout the system’s operation.
Three Phase 3 trials bring fenebrutinib a step closer to treating relapsing and primary progressive multiple sclerosis; however, fewer relapses do not necessarily mean broadly slower disability progression, and differences in death counts and liver risks will also test the balance of benefits and risks.
After four weeks of treatment, NEK7 and multiple inflammatory markers fell substantially, providing human evidence for a new anti-inflammatory strategy. But treatment discontinuations occurred in the higher-dose groups, and whether the drug can protect cardiovascular health still depends on bridging the gap between biomarkers and clinical efficacy.
The new reagent brings spinal muscular atrophy, severe combined immunodeficiency, and sickle cell disease into a single testing workflow. Earlier identification of risk can help secure more time for care, but screening must still be followed by confirmatory diagnosis and treatment.
Chemotherapy may weaken immune cells, but it may also boost cancer vaccines. A new study found that the timing of carboplatin and paclitaxel administration influenced vaccine effects. Corresponding immune changes appeared in patient samples, but whether this can improve clinical outcomes remains to be demonstrated in trials.
A genetic defect leaves the lungs without adequate protection and causes abnormal protein to accumulate in the liver. WVE-006 aims to address this source through RNA editing. The direction for a registration study is now clearer, but whether protein changes translate into organ protection still awaits clinical evidence.
A therapy designed to deliver the missing gene through a single intravenous infusion moves one step closer to patients in Europe. But acceptance of the application is only the beginning: obtaining marketing authorization and entering national healthcare systems involve further hurdles.
In adults with overweight or obesity and type 2 diabetes, adding eloralintide further improved tirzepatide’s effects on weight loss and blood glucose reduction. But in some dose groups, more than a quarter of participants discontinued treatment because of adverse events. Whether efficacy can translate into sustainable treatment will be key in the next stage.
A study using standardized patient videos demonstrates the potential of multimodal AI to assist with mental status assessments. But after recognizing speech and behavior, understanding subjective experiences such as delusions remains a key challenge on the path to clinical use.
From heart failure and inflammation to the menopausal transition, four teams will explore wearable patches that continuously measure biomarkers. The real test is whether the signals collected over time can be turned into reliable information usable in care.
Can it provide evidence of improved joint structure alongside relief from knee pain? Biosplice supports its application with two years of imaging follow-up, but confirmation that the submission is complete is only the starting point for review; efficacy and safety remain to be assessed.